메뉴 건너뛰기




Volumn 50, Issue 4, 2017, Pages

Lack of evidence of isoniazid efficacy for the treatment of MDR/XDR-TB in the presence of the katG 315T mutation

Author keywords

[No Author keywords available]

Indexed keywords

ISONIAZID; KATG PROTEIN; BACTERIAL PROTEIN; TUBERCULOSTATIC AGENT;

EID: 85031697705     PISSN: 09031936     EISSN: 13993003     Source Type: Journal    
DOI: 10.1183/13993003.01752-2017     Document Type: Letter
Times cited : (6)

References (10)
  • 1
    • 85038111499 scopus 로고    scopus 로고
    • Reply from the authors of limited benefit of the new shorter MDR-TB regimen in Europe
    • in press
    • van Leth F, Guenther G, Hoffmann H, et al. Reply from the authors of limited benefit of the new shorter MDR-TB regimen in Europe. Am J Respir Crit Care Med 2017; in press [https://doi.org/10.1164/rccm.201705-0995LE].
    • (2017) Am J Respir Crit Care Med
    • Van Leth, F.1    Guenther, G.2    Hoffmann, H.3
  • 3
    • 70349445065 scopus 로고    scopus 로고
    • Evaluation of wild-type MIC distributions as a tool for determination of clinical breakpoints for Mycobacterium tuberculosis
    • Schön T, Jureen P, Giske CG, et al. Evaluation of wild-type MIC distributions as a tool for determination of clinical breakpoints for Mycobacterium tuberculosis. J Antimicrob Chemother 2009; 64: 786–793.
    • (2009) J Antimicrob Chemother , vol.64 , pp. 786-793
    • Schön, T.1    Jureen, P.2    Giske, C.G.3
  • 4
    • 84982176724 scopus 로고    scopus 로고
    • Isoniazid minimal inhibitory concentrations of tuberculosis strains with katG mutation
    • Otto-Knapp R, Vesenbeckh S, Schönfeld N, et al. Isoniazid minimal inhibitory concentrations of tuberculosis strains with katG mutation. Int J Tuberc Lung Dis 2016; 20: 1275–1278.
    • (2016) Int J Tuberc Lung Dis , vol.20 , pp. 1275-1278
    • Otto-Knapp, R.1    Vesenbeckh, S.2    Schönfeld, N.3
  • 5
    • 84953418008 scopus 로고    scopus 로고
    • The 2014 Garrod Lecture: EUCAST–are we heading towards international agreement?
    • Kahlmeter G. The 2014 Garrod Lecture: EUCAST–are we heading towards international agreement? J Antimicrob Chemother 2015; 70: 2427–2439.
    • (2015) J Antimicrob Chemother , vol.70 , pp. 2427-2439
    • Kahlmeter, G.1
  • 6
    • 84885395522 scopus 로고    scopus 로고
    • Serum drug concentrations predictive of pulmonary tuberculosis outcomes
    • Pasipanodya JG, McIlleron H, Burger A, et al. Serum drug concentrations predictive of pulmonary tuberculosis outcomes. J Infect Dis 2013; 208: 1464–1473.
    • (2013) J Infect Dis , vol.208 , pp. 1464-1473
    • Pasipanodya, J.G.1    McIlleron, H.2    Burger, A.3
  • 7
    • 84899641391 scopus 로고    scopus 로고
    • Clinical characteristics and treatment outcomes of patients with low- And high-concentration isoniazid-monoresistant tuberculosis
    • Wang TY, Lin SM, Shie SS, et al. Clinical characteristics and treatment outcomes of patients with low- and high-concentration isoniazid-monoresistant tuberculosis. PLoS One 2014; 9: e86316.
    • (2014) Plos One , vol.9
    • Wang, T.Y.1    Lin, S.M.2    Shie, S.S.3
  • 8
    • 84926391806 scopus 로고    scopus 로고
    • Treatment outcome of patients with isoniazid mono-resistant tuberculosis
    • Chien JY, Chen YT, Wu SG, et al. Treatment outcome of patients with isoniazid mono-resistant tuberculosis. Clin Microbiol Infect 2015; 21: 59–68.
    • (2015) Clin Microbiol Infect , vol.21 , pp. 59-68
    • Chien, J.Y.1    Chen, Y.T.2    Wu, S.G.3
  • 9
    • 84880322995 scopus 로고    scopus 로고
    • Epidemiology of isoniazid resistance mutations and their effect on tuberculosis treatment outcomes
    • Huyen MNT, Cobelens FGJ, Buu TN, et al. Epidemiology of isoniazid resistance mutations and their effect on tuberculosis treatment outcomes. Antimicrob Agents Chemother 2013; 57: 3620–3627.
    • (2013) Antimicrob Agents Chemother , vol.57 , pp. 3620-3627
    • Huyen, M.N.T.1    Cobelens, F.G.J.2    Buu, T.N.3
  • 10
    • 84951962885 scopus 로고    scopus 로고
    • Clinical implications of molecular drug resistance testing for Mycobacterium tuberculosis: A TBNET/RESIST-TB consensus statement
    • Domínguez J, Boettger EC, Cirillo D, et al. Clinical implications of molecular drug resistance testing for Mycobacterium tuberculosis: a TBNET/RESIST-TB consensus statement. Int J Tuberc Lung Dis 2016; 20: 24–42.
    • (2016) Int J Tuberc Lung Dis , vol.20 , pp. 24-42
    • Domínguez, J.1    Boettger, E.C.2    Cirillo, D.3


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.